Skip to Content

Join the 'Pegasys' group to help and get support from people like you.

Pegasys News

HIV Therapy May Also Lower Risk for Hepatitis B, Study Says

Posted 12 Oct 2015 by Drugs.com

MONDAY, Oct. 12, 2015 – Not only does effective HIV therapy thwart the AIDS-causing virus, it may also reduce the risk for hepatitis B infection, a new study says. "What this means to us is that effective HIV therapy appears to restore an impairment in the immune response that protects someone with HIV from acquiring hepatitis B infection," study senior author Dr. Chloe Thio, a professor of medicine at Johns Hopkins University School of Medicine, said in a university news release. The study, published in the October issue of Annals of Internal Medicine, involved 2,400 gay and bisexual men who were enrolled in the Multicenter AIDS Cohort Study. Researchers found that the men successfully treated with HIV therapy had the same risk for hepatitis B infection as the men who did not have HIV. Hepatitis B is a virus that can damage the liver. The study showed HIV-positive men on HIV therapy ... Read more

Related support groups: Harvoni, HIV Infection, Valtrex, Acyclovir, Atripla, Hepatitis B, Sovaldi, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Truvada, Pegasys, Stribild, Complera, Triumeq, Baraclude, Victrelis, Famciclovir

Antiviral Therapy for Hepatitis C May Thwart Liver Cancer

Posted 23 Oct 2012 by Drugs.com

TUESDAY, Oct. 23 – Using antiviral drugs to treat patients with chronic hepatitis C infection may greatly reduce their risk of liver cancer, according to a new study. Hepatitis C is a leading cause of liver cancer and other liver diseases and is the leading cause of liver transplants. According to the U.S. Centers for Disease Control and Prevention, each year more than 15,000 Americans die from hepatitis C-related illness, such as cirrhosis and liver cancer. Deaths from the virus have been increasing for over a decade and are expected to increase in the coming years. In the new study, Nina Kimer and colleagues at Copenhagen University in Denmark reviewed eight published clinical trials on the use of antiviral therapy – interferon or pegylated interferon, or ribavirin, or a combination – in patients with chronic hepatitis C infection. Almost 1,200 patients in the studies received ... Read more

Related support groups: Hepatitis C, Ribavirin, Pegasys, PegIntron, Interferon Alfa-2B, Ribasphere, Copegus, Interferon Alfa-2A, Rebetol, Interferon Alfa-2B/Ribavirin, RibaPak, Peginterferon Alfa-2B, Intron A, Rebetron, Roferon-A, Peginterferon Alfa-2A, Virazole, Sylatron, RibaTab

Hepatitis C Treatment May Hamper Kids' Growth

Posted 13 Aug 2012 by Drugs.com

MONDAY, Aug. 13 – Children with hepatitis C who are treated with peginterferon alpha may experience growth-related side effects from the therapy, a new study reveals. Although weight changes are reversible, many children's height for their age may be lower even after the treatment for hepatitis C virus (HCV) ends, the researchers found. The study was published in the August issue of Hepatology. "While HCV in children is typically mild, some cases do progress to cirrhosis and liver cancer," lead study author Dr. Maureen Jonas, director of the Center for Childhood Liver Disease and medical director of the Liver Transplant Program at Boston Children's Hospital, said in a journal news release. "Treatment of HCV with peginterferon and ribavirin is approved for young children and offers the most benefit while liver disease is mild. However, there are concerns about the potential side effects ... Read more

Related support groups: Hepatitis C, Pegasys, PegIntron, Peginterferon Alfa-2B, Peginterferon Alfa-2A, Sylatron

Tailored Hepatitis C Therapy May Cut Treatment Time in Half

Posted 14 Sep 2011 by Drugs.com

WEDNESDAY, Sept. 14 – Patients infected with hepatitis C virus who have an early favorable response to a new three-drug regimen can be cured of the disease in half the normal time, a new study says. In the multinational study, researchers showed that tailoring patients' treatment regimen to their response to the drugs, which is known as response-guided therapy, enabled many patients to cut treatment time in half and still achieve the same cure rates. The paper was published Sept. 15 in the New England Journal of Medicine. "Patients treated with this regimen who clear virus from their blood by 4 weeks of therapy and who remain virus negative after 12 weeks of therapy can shorten total treatment time from 48 to 24 weeks and have an excellent chance of hepatitis C virus cure," said the study's lead author, Dr. Kenneth E. Sherman, Gould Professor of Medicine and director of the digestive ... Read more

Related support groups: Hepatitis C, Ribavirin, Incivek, Pegasys, Victrelis, PegIntron, Ribasphere, Copegus, Telaprevir, Boceprevir, Rebetol, Interferon Alfa-2B/Ribavirin, Peginterferon Alfa-2B, Rebetron, RibaPak, Peginterferon Alfa-2A, Virazole, RibaTab, Sylatron

Top Hepatitis C Treatments Equally Effective

Posted 22 Jul 2009 by Drugs.com

WEDNESDAY, July 22 – A landmark hepatitis C virus study shows that the top two treatment options are equally effective and safe. The long-awaited study, thought to be the largest of its kind, is important for the 180 million people worldwide – 4 million in the United States – who are infected with hepatitis C virus and at risk for liver scarring, organ failure and death. Hepatitis C is America's leading cause of liver failure, liver cancer and liver transplantation. The disease is transmitted by contact with blood through sexual activities, drug use or personal care items. The study of 3,070 adults at Johns Hopkins and 118 other U.S. medical centers showed that treating patients with either of the two standard antiviral therapies is safe and helps prevent liver damage. The report appears online July 22 in the New England Journal of Medicine. The drug therapies – peginterferon ... Read more

Related support groups: Hepatitis C, Pegasys, PegIntron, Copegus

Hepatitis C Therapy Useless for Some

Posted 3 Dec 2008 by Drugs.com

WEDNESDAY, Dec. 3 – Maintenance therapy using low-dose peginterferon doesn't help patients with advanced chronic hepatitis C who haven't responded to an initial round of treatment, new research suggests. The study also showed a surprising health decline in patients with liver disease over the course of four years. "This course of treatment had been adopted by a number of doctors in the U.S. and in other countries, though it had yet to be proven to work. That practice should be stopped, based on the results of this trial. There is no rationale for using maintenance therapy. The treatment is clearly ineffective," study author Dr. Adrian Di Bisceglie, chief of hepatology and co-director of the Liver Center at Saint Louis University, said in a university news release. About half of patients with chronic hepatitis C fully recover after an initial course of peginterferon and ribavirin ... Read more

Related support groups: Hepatitis C, Pegasys, PegIntron

Ask a Question

Further Information

Related Condition Support Groups

Hepatitis B, Hepatitis C

Pegasys Patient Information at Drugs.com